Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), the developer of cancer immunotherapies, has announced key changes to its executive team.
Investors were told Dr Sally Adams is set to retire as chief development officer to be succeeded by Dr Callum Scott, who will assume the role of head of development with immediate effect.
Scott brings with him 15 years in R&D. His last position was as technical transfer & formulation development manager with Allergy Therapeutics, which saw him leading critical chemistry, manufacturing, and controls and product development phases for Allergy's VLP Peanut project.
"Firstly, on behalf of the Scancell board, I would like to express our sincere gratitude to Sally for her expertise and support over the last 15 years, both on the board and leading clinical development," said chief executive, professor Lindy Durrant.
"She has been instrumental in establishing a highly motivated development team and has worked tirelessly to bring our highly differentiated and valuable cancer vaccines through to the clinic. We wish her all the best for the future.
"I would also like to warmly welcome Callum to Scancell. His understanding of the challenges involved in developing, registering, and commercialising novel biologics will be of great value to Scancell as we continue to develop our lead assets SCIB1 and Modi-1 through later stage clinical development."